Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice.

Cancers (Basel) · 2023 · PMC10649131 · PMID 37958441

Europe PMC DOI

hedged sentence

0.0556

closest p · 1.1× alpha

0.0556

boldest claim

The sentences

did not reach statistical significancep = 0.0556so close (0.05 < p ≤ 0.1)

After sIPTW, the median OS was 31.4 months (95% CI: 25.1–37.8) for the palbociclib plus AI group compared with 21.4 months (95% CI: 14.8–31.6) for the AI-alone group, but the difference did not reach statistical significance (HR = 0.73, 95% CI: 0.52–1.01; p = 0.0556; Figure 2 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.